Jove
Visualize
Contact Us

Related Experiment Videos

Chemotherapy for gastrointestinal malignancy

L D Van der Veer, J A Balint

    The American Journal of Gastroenterology
    |July 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection.

    Gut·2003
    Same author

    Decisions at the end of life.

    Croatian medical journal·2000
    Same author

    Brief encounters: speaking with patients.

    Annals of internal medicine·1999
    Same author

    Fair treatment of alcoholic patients in the context of liver transplantation.

    Alcoholism, clinical and experimental research·1997
    Same author

    Performance-based assessment of moral reasoning and ethical judgment among medical students.

    Academic medicine : journal of the Association of American Medical Colleges·1994
    Same author

    Remedial medical education.

    Archives of internal medicine·1994
    Same journal

    Calendar of Courses, Symposiums and Conferences.

    The American journal of gastroenterology·2026
    Same journal

    Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

    The American journal of gastroenterology·2026
    Same journal

    ACG Clinical Guideline: Colonic Diverticulitis.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    2026 CME Information.

    The American journal of gastroenterology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Gastrointestinal cancers are often unresectable, with chemotherapy offering limited survival benefits for esophageal, gastric, and pancreatic cancers. Colorectal cancer shows a modest response, highlighting the need for individualized treatment decisions.

    Area of Science:

    • Oncology
    • Gastroenterology

    Background:

    • Gastrointestinal cancers frequently present as unresectable at diagnosis, leading to poor prognoses.
    • Chemotherapy is a common treatment modality aimed at prolonging life and managing symptoms in these patients.

    Purpose of the Study:

    • To review the efficacy of chemotherapy in various advanced gastrointestinal malignancies.
    • To discuss the balance between potential palliation and adverse side effects of chemotherapy.

    Main Methods:

    • Literature review of chemotherapy response rates and survival outcomes in esophageal, gastric, pancreatic, and colorectal cancers.
    • Analysis of patient data regarding response to chemotherapy and survival duration.

    Main Results:

    • Esophageal squamous cell carcinoma demonstrates poor response to chemotherapy.

    Related Experiment Videos

  • Gastric carcinoma shows higher response rates but limited overall survival improvement.
  • Advanced pancreatic carcinoma has transient responses with short median survival.
  • Less than 20% of advanced colorectal cancers respond to chemotherapy, with responders living several months longer.
  • Conclusions:

    • Chemotherapy offers limited benefits for most advanced gastrointestinal cancers, necessitating careful consideration of risks and benefits.
    • Adjuvant chemotherapy's efficacy is still under evaluation, but shows potential for cautious optimism.